Consensus Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-19 pm EDT			5-day change	1st Jan Change
5.35 ^USD	-4.63%		-6.30%	+13.83%

Apr. 10	Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	CI
Mar. 27	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT

Evolution of the average Target Price on Aprea Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e5d3e417876cfda26850713369844.fFjXLqTAUxkodEsMSF6lRJM6kt51ZjCjZ29uDp4T38U.Ti2lR9z1JCxFMxJfOgbuFMN_outFMlWTNhY3dPJ6mbMkApp3yvQMLE8_LA~e96d389631967bd66af20d62575bab3c

Analyst Recommendations on Aprea Therapeutics, Inc.

Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	Mar. 27	MT
Wedbush Raises Aprea Therapeutics' PT to $9 From $3, Says Keeps Outperform Rating; Continues to View Shares as 'Intriguingly Valued'	23-04-10	MT
Maxim Initiates Aprea Therapeutics at Buy Rating With $16 Price Target	23-03-10	MT
HC Wainwright Assumes Aprea Therapeutics at Buy with $3 Price Target	22-10-10	MT
Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target	22-07-07	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold Rating	22-05-25	MT
HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral Rating	22-03-16	MT
RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier	22-03-16	MT
APREA THERAPEUTICS : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral	21-08-20	MT
APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating	21-08-16	MT
APREA THERAPEUTICS : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Following Clinical Hold on Myeloid/Lymphoid Program, Adjusts PT to $4 From $10	21-08-16	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $5 From $6 Amid FDA Hold on Lymphoid Malignancy Trial; Sector Perform-Speculative Risk Rating Kept	21-08-13	MT
APREA THERAPEUTICS : Morgan Stanley Lowers Aprea Therapeutics to Underweight From Equal-Weight, Price Target to $3 From $5	21-08-13	MT
APREA THERAPEUTICS : RBC Reduces Price Target on Aprea Therapeutics to $6 From $7, Maintains Sector Perform, Speculative Risk	21-08-09	MT
DJ Industrial : Equities Little Changed in US Midday Trading as Markets Await Federal Reserve Rate Decision, Outlooks	21-06-16	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $7 From $8, Maintains Sector Perform, Speculative Risk	21-05-07	MT
APREA THERAPEUTICS : RBC Cuts Price Target on Aprea Therapeutics to $8 From $10, Maintains Sector Perform-Speculative Risk Rating	21-03-17	MT
APREA THERAPEUTICS : Morgan Stanley Adjusts Aprea Therapeutics' Price Target to $6 From $34, Keeps Equal-Weight Rating	20-12-29	MT
APREA THERAPEUTICS : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $6 From $30, Maintains Neutral Rating	20-12-29	MT
APREA THERAPEUTICS : RBC Capital Downgrades Aprea Therapeutics to Sector Perform From Outperform, Adjusts PT to $10 From $40	20-12-28	MT
APREA THERAPEUTICS : Baird Downgrades Aprea Therapeutics to Neutral From Outperform	20-12-28	MT
APREA THERAPEUTICS : Morgan Stanley Adjusts Aprea Therapeutics PT to $34 From $39, Maintains Equal Weight Rating	20-12-16	MT
APREA THERAPEUTICS : Berenberg Bank Initiates Coverage on Aprea Therapeutics With Buy Rating, $37 Price Target	20-12-16	MT